Stereotaxis reported Q1 results on May 12, and the headline story this week is not the print itself — it is the sharp rebuild in short positioning that arrived ahead of it.
Short interest climbed 15.7% over the past week to 5.4% of free float, the fastest seven-day accumulation in months. The move accelerated noticeably from May 8 onward, lifting the ORTEX short score to 57.4 — up from 52.7 just two weeks earlier and the highest reading in the recent series. That pace of change, more than the absolute level, is what makes the setup worth watching. Shorts had spent most of late April unwinding from above 5% — SI dipped as low as 4.6% in mid-April — before reversing sharply into the print.
The borrow market remains orderly. Cost to borrow is a low 0.65%, up modestly on the week but well within its recent range. Availability is neither tight nor loose, and the lending pool shows no squeeze pressure at current levels. The stock's days-to-cover is 14.5 per official FINRA data, a figure that sits in just the 5th percentile of its universe — meaning DTC is low relative to peers, and a quick cover is technically feasible. Options positioning reinforces the lack of urgency on the bearish side: the put/call ratio is 0.060, actually below its 20-day average and more than a standard deviation beneath it. Call open interest dominates heavily, a reminder that options activity here is structurally thin and skewed bullish by default.
The Street remains constructive, though Piper Sandler trimmed its target to $3.50 from $4.00 on May 13 while holding an Overweight rating — a signal of tempered conviction rather than a change in direction. With the stock at $1.92, the mean analyst price target of $4.13 implies more than 100% upside. That gap is substantial, but it partly reflects the stock's 18% year-to-date decline and the Street's long-held optimism on the robotic electrophysiology story. Bulls point to the company's collaboration with CardioFocus on a robotic Pulsed Field Ablation system and the path toward cash-flow positivity. Bears flag FDA clearance timelines, reimbursement risk, and competition from better-capitalised medtech platforms. EPS surprise ranks at the 57th percentile — decent but not a consistent beat machine.
Joseph Kiani, the company's largest named individual holder with a 10.4% stake, added 1.25 million shares as recently as March 2026. Dafna Capital Management holds 14% of shares outstanding and has been a long-term anchor. That concentrated ownership picture gives the stock an unusual dynamic: a small free float, patient specialist holders, and a short interest that — while rebuilding — is still not large enough in absolute terms to create acute squeeze mechanics on its own.
What to watch next is straightforward: whether the short rebuild continues after the earnings print, and whether Piper Sandler's target cut represents the beginning of a broader Street reset or a one-off post-results recalibration.
See the live data behind this article on ORTEX.
Open STXS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
